Actinium CEO Interviewed for “Small Stocks: Big Money” Airing on Fox Business and Bloomberg
NEW YORK-- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces the availability of an exclusive interview with its President and CEO, Kaushik J. Dave, Ph.D.
Dr. Dave was interviewed by “The RedChip Money Report: Small Stocks Big Money”™ hosted by Dave Gentry, a leading authority on small-cap stocks. Mr. Gentry is the President and CEO of RedChip Companies, an international small-cap research, investor relations, and media company.
During the interview, Dr. Dave provided an overview of Actinium, its patented alpha-emitter technology, current clinical development pipeline, and the multi-billion dollar market opportunity the Company is pursuing. The full interview is available at:
The interview will air on Fox Business nationwide on Thursday, April 17, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 19, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Saturday, April 19, 2014 at 3:30 p.m. GMT and Sunday, April 20, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday, April 20, 2014 at 3:30 p.m. HKT.
"The RedChip Money Report: Small Stocks Big Money" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies, and reaches 80 million homes on Fox Business; 139 million homes in more than 50 cities on Bloomberg Europe; and an additional 13.5 million homes in a dozen countries on Bloomberg Asia.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Corey Sohmer, 646-459-4201
Source: Actinium Pharmaceuticals, Inc.
Released April 3, 2014